Robert Schvarcz

2.7k total citations
48 papers, 2.1k citations indexed

About

Robert Schvarcz is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, Robert Schvarcz has authored 48 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Hepatology, 30 papers in Epidemiology and 12 papers in Rheumatology. Recurrent topics in Robert Schvarcz's work include Hepatitis C virus research (39 papers), Liver Disease Diagnosis and Treatment (21 papers) and Hepatitis B Virus Studies (20 papers). Robert Schvarcz is often cited by papers focused on Hepatitis C virus research (39 papers), Liver Disease Diagnosis and Treatment (21 papers) and Hepatitis B Virus Studies (20 papers). Robert Schvarcz collaborates with scholars based in Sweden, Austria and United States. Robert Schvarcz's co-authors include Ola Weiland, Annette Bruchfeld, Olle Reichard, Karin Lindahl, Jan Andersson, Lars Ståhle, Aril Frydén, Gunnar Norkrans, Hans Glaumann and Elisabeth Ståhle and has published in prestigious journals such as The Lancet, Hepatology and The Journal of Infectious Diseases.

In The Last Decade

Robert Schvarcz

47 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert Schvarcz Sweden 24 1.8k 1.6k 315 299 112 48 2.1k
Inmaculada Castillo Spain 30 2.2k 1.2× 2.0k 1.2× 295 0.9× 235 0.8× 173 1.5× 93 2.6k
J. Guardia Spain 18 1.9k 1.1× 1.7k 1.1× 186 0.6× 302 1.0× 158 1.4× 38 2.2k
Paul Neuwald United States 15 1.7k 1.0× 1.7k 1.0× 307 1.0× 409 1.4× 181 1.6× 20 2.3k
Harvey J. Alter United States 6 1.9k 1.0× 1.7k 1.1× 154 0.5× 329 1.1× 139 1.2× 7 2.4k
Jacqueline C. Melpolder United States 9 2.9k 1.6× 2.6k 1.6× 212 0.7× 380 1.3× 187 1.7× 11 3.4k
Denis Ouzan France 28 2.1k 1.2× 2.0k 1.2× 166 0.5× 305 1.0× 78 0.7× 128 2.4k
Christine J. Weegink Netherlands 22 2.2k 1.2× 1.9k 1.2× 193 0.6× 634 2.1× 137 1.2× 53 2.4k
Flavia Bortolotti Italy 36 4.3k 2.3× 4.5k 2.7× 154 0.5× 316 1.1× 140 1.3× 134 4.8k
L Viladomiu Spain 14 1.6k 0.9× 1.5k 0.9× 73 0.2× 179 0.6× 39 0.3× 25 1.8k
K. Krawczyński United States 28 2.1k 1.2× 1.3k 0.8× 175 0.6× 913 3.1× 139 1.2× 48 2.6k

Countries citing papers authored by Robert Schvarcz

Since Specialization
Citations

This map shows the geographic impact of Robert Schvarcz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Schvarcz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Schvarcz more than expected).

Fields of papers citing papers by Robert Schvarcz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Schvarcz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Schvarcz. The network helps show where Robert Schvarcz may publish in the future.

Co-authorship network of co-authors of Robert Schvarcz

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Schvarcz. A scholar is included among the top collaborators of Robert Schvarcz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Schvarcz. Robert Schvarcz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Söderholm, Jonas, Katharina Büsch, Jan Kövamees, et al.. (2017). Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis. Journal of Hepatology. 68(5). 904–911. 33 indexed citations
2.
Lindahl, Karin, Lars Ståhle, Tony Carlsson, et al.. (2015). High-Dose Ribavirin Enhances Early Virological Response in Hepatitis C Genotype 1–Infected Patients. Therapeutic Drug Monitoring. 37(6). 745–750. 6 indexed citations
3.
Weiland, Ola, A. Gerson Hollander, L. Mattsson, et al.. (2008). Lower‐than‐standard dose peg‐IFN alfa‐2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight‐based ribavirin. Journal of Viral Hepatitis. 15(9). 641–645. 16 indexed citations
4.
Nowak, Piotr, Robert Schvarcz, Bo‐Göran Ericzon, Leo Flamholc, & Anders Sönnerborg. (2003). Follow-up of Antiretroviral Treatment in Liver Transplant Recipients with Primary and Chronic HIV Type 1 Infection. AIDS Research and Human Retroviruses. 19(1). 13–19. 12 indexed citations
5.
Bruchfeld, Annette, Elisabeth Ståhle, Jan Andersson, & Robert Schvarcz. (2001). Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection – a pilot study. Journal of Viral Hepatitis. 8(4). 287–292. 109 indexed citations
6.
7.
Carlsson, Thomas, Karin Lindahl, Robert Schvarcz, et al.. (2000). HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin. Journal of Viral Hepatitis. 7(6). 409–413. 23 indexed citations
8.
Zhang, Zhu‐Xu, David R. Milich, Darrell L. Peterson, et al.. (1997). Interferon‐α Treatment Induces Delayed CD4 Proliferative Responses to the Hepatitis C Virus Nonstructural Protein 3 Regardless of the Outcome of Therapy. The Journal of Infectious Diseases. 175(6). 1294–1301. 39 indexed citations
9.
Schalm, Solko W., Bettina E. Hansen, Liliana Chemello, et al.. (1997). Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Journal of Hepatology. 26(5). 961–966. 161 indexed citations
10.
Schvarcz, Robert, Yukio Ando, Anders Sönnerborg, & Ola Weiland. (1995). Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience.. PubMed. 23 Suppl 2. 17–21. 64 indexed citations
11.
Schvarcz, Robert, Zhibing Yun, Anders Sönnerborg, & Ola Weiland. (1995). Combined treatment with interferon alpha‐2b and ribavirin for chronic hepatitis C in patients with a previous non‐response or non‐sustained response to interferon alone. Journal of Medical Virology. 46(1). 43–47. 90 indexed citations
12.
Schvarcz, Robert, et al.. (1994). Treatment of chronic replicative hepatitis B virus infection with short-term continuous infusion of foscarnet. Infection. 22(5). 330–332. 3 indexed citations
13.
Reichard, Olle, Gunnar Norkrans, Rune Wejstål, et al.. (1994). Histological outcome in patients with chronic hepatitis C given a 60‐week interferon alfa‐2b treatment course. Liver International. 14(4). 169–174. 17 indexed citations
14.
Weiland, Ola & Robert Schvarcz. (1992). Hepatitis C: Virology, Epidemiology, Clinical Course, and Treatment. Scandinavian Journal of Gastroenterology. 27(5). 337–342. 17 indexed citations
15.
Schvarcz, Robert, Hans Glaumann, Ola Weiland, et al.. (1991). Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B/C hepatitis: Long-term outcome and effect of increased interferon doses in non-responders. Scandinavian Journal of Infectious Diseases. 23(4). 413–420. 15 indexed citations
16.
Reichard, Olle, Jan Andersson, Robert Schvarcz, & Ola Weiland. (1991). Ribavirin treatment for chronic hepatitis C. The Lancet. 337(8749). 1058–1061. 227 indexed citations
17.
Schvarcz, Robert, Madeleine von Sydow, & Ola Weiland. (1990). Autoimmune Chronic Active Hepatitis: Changing Reactivity for Antibodies to Hepatitis C Virus after Immunosuppressive Treatment. Scandinavian Journal of Gastroenterology. 25(11). 1175–1180. 23 indexed citations
18.
Weiland, Ola, Robert Schvarcz, Rune Wejstål, Gunnar Norkrans, & Aril Frydén. (1990). Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience. Journal of Hepatology. 11. S57–S62. 56 indexed citations
19.
Schvarcz, Robert, Ola Weiland, Rune Wejstål, et al.. (1989). A Randomized Controlled Open Study of Interferon Alpha-2b Treatment of Chronic IMon-A, Non-B Posttransfusion Hepatitis: No Correlation of Outcome to Presence of Hepatitis C Virus Antibodies. Scandinavian Journal of Infectious Diseases. 21(6). 617–625. 63 indexed citations
20.
Schvarcz, Robert, Ola Weiland, & Hans Glaumann. (1988). Alpha Interferon Treatment of Chronic Non-A, Non-B Hepatitis Caused by Intravenous Gammaglobulin. Scandinavian Journal of Infectious Diseases. 20(2). 231–232. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Inmaculada Castillo Breakdown of academic impact, for papers by J. Guardia Breakdown of academic impact, for papers by Paul Neuwald Breakdown of academic impact, for papers by Harvey J. Alter Breakdown of academic impact, for papers by Jacqueline C. Melpolder Breakdown of academic impact, for papers by Denis Ouzan Breakdown of academic impact, for papers by Christine J. Weegink Breakdown of academic impact, for papers by Flavia Bortolotti Breakdown of academic impact, for papers by L Viladomiu Breakdown of academic impact, for papers by K. Krawczyński
Rankless by CCL
2026